ChemoCentryx, Inc.

850 Maude Avenue
Mountain View
California
94043
United States

Tel: 650-210-2900
Fax: 650-210-2910

About ChemoCentryx, Inc.

"People Deserve Better Medicine and not just a longer life---a better life."

Located in the heart of the Silicon Valley, ChemoCentyx is a biotechnology company that focuses on chronic kidney diseases, immuno-oncology, and other autoimmune and inflammatory diseases.

Our vision can only be accomplished through talented people who share our culture and values.

We have created a corporate culture of scientific innovation, placing emphasis on hard work, honesty, and industry-leading technology in a fun, team-oriented atmosphere. We treat each other with respect at all times. We expect employees to add value as individuals and as team members. We work hard to nurture this environment.

As a late clinical development stage company, we are focused on a pipeline that discovers, develops and commercializes orally-administered therapeutics.

"ChemoCentryx: Great Science, Great Medicine"

ChemoCentryx, Inc.

About ChemoCentryx, Inc.

236 articles about ChemoCentryx, Inc.

ChemoCentryx, Inc. Announces Appointment of James L. Tyree to the Company's Board of Directors

ChemoCentryx, Inc. to Present at the 2012 Wells Fargo Securities Healthcare Conference

ChemoCentryx, Inc. Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress

ChemoCentryx, Inc. Announces Transfer of Existing Shares Between Current Stockholders

ChemoCentryx, Inc. Announces First Quarter 2012 Financial Results

ChemoCentryx, Inc. Appoints Joseph M. Feczko, M.D. to Company's Board of Directors

ChemoCentryx, Inc. to Present at the 19th Annual Future Leaders in the Biotech Industry Conference

ChemoCentryx, Inc. Announces 2011 Fourth Quarter and Full Year Financial Results

ChemoCentryx, Inc. Completes IPO

ChemoCentryx, Inc. Announces Pricing of Initial Public Offering

ChemoCentryx, Inc. Sets $14-$16 Range for IPO

GlaxoSmithKline Exercises Option to License ChemoCentryx, Inc.'s CCR1 Inhibitor, CCX354, for the Treatment of Rheumatoid Arthritis

ChemoCentryx, Inc. Initiates a Phase II Clinical Trial For CCX140, A Novel Inhibitor of the Chemokine Receptor CCR2 for the Treatment of Diabetic Nephropathy

ChemoCentryx, Inc. Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology

ChemoCentryx, Inc. Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis

ChemoCentryx, Inc. Reports CCX140-B Meets Primary Endpoint and Demonstrates Clinical Efficacy in Phase II Study in Type 2 Diabetes

ChemoCentryx, Inc. Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes

ChemoCentryx, Inc. Reports CCX140, a Novel Oral CCR2 Antagonist, Demonstrates Clinical Activity on Glycemic Indices in a Phase II Study in Type 2 Diabetes

ChemoCentryx, Inc. Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23

GlaxoSmithKline and ChemoCentryx, Inc. Announce Initiation of Phase III study of GSK'786, formerly Traficet-EN(TM), for the Treatment of Crohn's Disease